Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents

Amer M. Zeidan, Sophie (jui-Hua) Tsai, Milad Karimi, Jordana Schmier, Sayeli Jayade, Evangelos Zormpas, Audrey Hassan, Desiree Ruiters, Cindy Anthony, Kala Hill, Tim Wert, Marc Botteman

Blood (2022) 140 (Supplement 1): 10847–10848.

https://doi.org/10.1182/blood-2022-167360

Published: 2022

Journal Articles

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Namita Joshi, PhD MS, BPharm, Xinyi Ng, Marc Botteman, MS, MA, Nanxin Li, Rachel Shah, BS, Nisha Jain, Nicole Lyn, Jun Su

Blood (2019) 134 (Supplement_1): 2122.

https://doi.org/10.1182/blood-2019-126774

Published: 2019

Journal Articles

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Marc Botteman, MS, MA, Ruchit Shah, PhD, Linlin Luo, MSc, Zhenming Shun, PhD, Saurabh Ray, PhD

Blood (2019) 134 (Supplement_1): 382.

https://doi.org/10.1182/blood-2019-123554

Published: 2019

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

Journal Articles

Real-World Differences in Characteristics and Survival of Relapsed AML Patients with and without Transplant

Abdalla Aly, Saurabh Ray, Anuj Shah, PhD, Marc Botteman, MS, MA

Blood (2018) 132 (Supplement 1): 2297.

https://doi.org/10.1182/blood-2018-99-118621

Published: 2018

Journal Articles

Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

Abdalla Aly, PhD, Bela Bapat, MA, Saurabh Ray, PhD, Zhiyong Chen, PhD, Marc Botteman, MSc, MA

Blood (2017) 130 (Supplement 1): 3386.

https://doi.org/10.1182/blood.V130.Suppl_1.3386.3386

Published: 2017

Journal Articles

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Sonya J Snedecor, PhD, Xiang Ji, MS, Matthew Magestro, Andrew M Stein, PhD, Marc Botteman, MSc, MA

Blood (2012) 120 (21): 4441.

https://doi.org/10.1182/blood.V120.21.4441.4441

Published: 2012

Journal Articles

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Marc Botteman, MSc, MA, Matthew Magestro, Alaa Fadhil Alwan, MD, Paul W Manley, PhD, Oleg Zernovak, MD, Richard C. Woodman

Blood (2012) 120 (21): 4439.

https://doi.org/10.1182/blood.V120.21.4439.4439

Published: 2012

Journal Articles

Cost-Effectiveness of Adding Imatinib to Chemotherapy in Adult Patients with Chromosom-Positive Acute Lymphoblastic Leukemia (Ph+ALL): A Canadian Perspective

Khalid El Ouagari, PhD, Kimbach Tran, MPH, MS, Jennifer Stephens, PharmD, Marc Botteman, MSc, MA

Blood (2008) 112 (11): 2401.

https://doi.org/10.1182/blood.V112.11.2401.2401

Published: 2008

Journal Articles

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Jennifer Stephens, Kim Carpiuc, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4586.

https://doi.org/10.1182/blood.V110.11.4586.4586

Published: 2007

Journal Articles

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Kim Carpiuc, Khalid El Ouagari, PhD, Jennifer Stephens, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4587.

https://doi.org/10.1182/blood.V110.11.4587.4587

Published: 2007

NARROW

Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents

Patients' and Caregivers' Preferences for Different Hemophilia a Treatment Attributes

Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Real-World Differences in Characteristics and Survival of Relapsed AML Patients with and without Transplant

Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

Estimating Long-Term Life Expectancy in Philadelphia Chromosome Positive (Ph+) Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results of A Microsimulation Model

Assessment of Clinical Safety and Estimate of Survival in Iraqi Patients with Chronic Myeloid Leukemia Switched From Glivec (β-Crystalline Form of Imatinib Mesylate) to an α-Crystalline Copy of Imatinib Mesylate

Cost-Effectiveness of Adding Imatinib to Chemotherapy in Adult Patients with Chromosom-Positive Acute Lymphoblastic Leukemia (Ph+ALL): A Canadian Perspective

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only